💊

Alecensa

alectinib

Carcinoma, Non-Small-Cell Lung

✅ Authorised

✅

No active alerts

This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib.

⚠️ Patient safety

Official EMA page

https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa